If I got that number right, they will.
Just ride that thing. Don't sell!!!!
$70 easy by Xmas.
EDIT:
I was right Stoney!
Its on the wires now.
They beat buy $0.59
Last edited:
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
Just ride that thing. Don't sell!!!!
$70 easy by Xmas.
EDIT:
I was right Stoney!
Its on the wires now.
They beat buy $0.59
--Copart reports Q4 non-GAAP EPS 1.03, consensus 91c 16:47 CPRT Reports Q4 revenue $748.6M, consensus $690.87M.------
--LOVE is up $5 in pre
-- I'll be honest I do not know this company and I jumped right out the other day when it dived! I just did not have the faith--- this is what happens when you take someone else's idea!!!
But--> You all may have been correct!--BeyondSpring initiated with an Outperform at Baird 16:28 BYSI Baird analyst Joel Beatty initiated coverage of BeyondSpring with an Outperform rating and $50 price target.
--LOVE is up $5 in pre
-- I'll be honest I do not know this company and I jumped right out the other day when it dived! I just did not have the faith--- this is what happens when you take someone else's idea!!!
But--> You all may have been correct!--BeyondSpring initiated with an Outperform at Baird 16:28 BYSI Baird analyst Joel Beatty initiated coverage of BeyondSpring with an Outperform rating and $50 price target.
Your system is unbelievable I did not see any of this info
I was right Stoney!
Its on the wires now.
They beat buy $0.59
I was right Stoney!
Its on the wires now.
They beat buy $0.59
Oh boy. My old trainer he buys this crypto and it's really annoying. He was way up on a Crypto that gives interest sounded lie a good idea it may have been Ripple and I just heard Coinbase was going to try the same thing and got shut down by the SEC and that this cannot be good for his holding. I told him to cash out and buy back in but they roll over because of the interest...
Lovesac reports Q2 EPS (52c), consensus (8c) 07:04 LOVE Reports Q2 revenue $102.4M, consensus $90.97M. Shawn Nelson, CEO, stated, "Across nearly every key operating metric, Lovesac's quarterly results affirm the fundamental efficacy of our disruptive home furnishings model, the competitive advantages of our diversified supply chain and resulting strong in-stock positions, along with growing brand awareness. To that end, our very strong second quarter performance marks 14 consecutive quarters of 25%+ sales growth with profitability nicely ahead of expectations driven primarily by lower promotions and fixed cost leverage on this quarter's 65% sales increase."
Lovesac reports Q2 SSS up 39.5% 07:04 LOVE
>> Lovesac: Q3 'off to a strong start' 07:04 LOVE
Lovesac reports Q2 SSS up 39.5% 07:04 LOVE
>> Lovesac: Q3 'off to a strong start' 07:04 LOVE
I think we would rather they bought them but.....
Marqeta partners with Zip Co. in Australia to boost BNPL offering 07:06 MQ Marqeta announced a continued partnership with Zip Co. in Australia, completing the first year of powering the global Buy Now Pay Later BNPL company which provides fast and seamless solutions that simplify how people pay, everywhere. Marqeta's modern card issuing platform is built with open APIs and has enabled Zip to bring new payments products to market faster, offering customers a line of credit attached to their account rather than an installment plan. Customers can make multiple transactions using their Zip Pay account, but repay their Zip balance with a single installment plan, creating a more streamlined user experience. Zip customers have grown strongly over the last 3 years, and now reach over 2.8 million users in Australia and 7.3 million globally, according to Zip. Both companies have seen significant growth and momentum last quarter: Zip cited 176% growth in transactional volumes of AUD, up to $5.8B, while Marqeta reported a 350% year-over-year increase in BNPL net revenue for Q2 2021. In addition, Zip offers a "Shop Anywhere" product that issues a single-use virtual card in the Zip app that enables customers to spend money anywhere in the world that accepts Visa. According to Zip, its transaction volume has grown significantly in the 12 months since partnering with Marqeta.
Marqeta partners with Zip Co. in Australia to boost BNPL offering 07:06 MQ Marqeta announced a continued partnership with Zip Co. in Australia, completing the first year of powering the global Buy Now Pay Later BNPL company which provides fast and seamless solutions that simplify how people pay, everywhere. Marqeta's modern card issuing platform is built with open APIs and has enabled Zip to bring new payments products to market faster, offering customers a line of credit attached to their account rather than an installment plan. Customers can make multiple transactions using their Zip Pay account, but repay their Zip balance with a single installment plan, creating a more streamlined user experience. Zip customers have grown strongly over the last 3 years, and now reach over 2.8 million users in Australia and 7.3 million globally, according to Zip. Both companies have seen significant growth and momentum last quarter: Zip cited 176% growth in transactional volumes of AUD, up to $5.8B, while Marqeta reported a 350% year-over-year increase in BNPL net revenue for Q2 2021. In addition, Zip offers a "Shop Anywhere" product that issues a single-use virtual card in the Zip app that enables customers to spend money anywhere in the world that accepts Visa. According to Zip, its transaction volume has grown significantly in the 12 months since partnering with Marqeta.
OK, I'll give away a great (VZ) secret here to our many readers Stoney that never post, and all the WSB's types that read us too.
The "system" is easy.
You use an RSS feed for the stock in question at this link:
https://www.businesswire.com/portal/site/home/news/subject/?vnsId=31350
Now I know you Stoney... you'll be like "what's an RSS feed?"
It's easy.
Look up how to do it.
Folks seem to be ga ga over Lu Lu
Lululemon price target raised to $500 from $450 at JPMorgan »
JPMorgan expects 'sizable equity issue' from State Street after deal 07:16 STT JPMorgan analyst Vivek Juneja expects a "sizable equity issue" by State Street following its "fully priced" acquisition of Brown Brothers Harriman's Investor Services business. In its last acquisition, the issuance came within a week, Juneja tells investors in a research note. The analyst sys Brown Brothers Harriman has grown at about half the rate of State Street and Bank of NY in recent years due to multiple large client losses. Juneja keeps a Neutral rating on State Street shares.
One of my favorite SPAC's.
Blade Air Mobility initiated with an Overweight at JPMorgan 07:23 BLDE JPMorgan analyst Bill Peterson initiated coverage of Blade Air Mobility with an Overweight rating and $16 price target. Blade is a "first mover" in urban air mobility and has "strong" growth momentum that should accelerate on rising brand awareness and with increased use of on-demand and scheduled flight services, Peterson tells investors in a research note. As an agnostic user of aircraft, Blade's model does not depend on the success of any one or a handful of electric vertical aircraft companies, says the analyst. H believes Blade may emerge as the leader of what can be considered "ride-sharing in the skies."
Lululemon price target raised to $500 from $450 at JPMorgan »
JPMorgan expects 'sizable equity issue' from State Street after deal 07:16 STT JPMorgan analyst Vivek Juneja expects a "sizable equity issue" by State Street following its "fully priced" acquisition of Brown Brothers Harriman's Investor Services business. In its last acquisition, the issuance came within a week, Juneja tells investors in a research note. The analyst sys Brown Brothers Harriman has grown at about half the rate of State Street and Bank of NY in recent years due to multiple large client losses. Juneja keeps a Neutral rating on State Street shares.
One of my favorite SPAC's.
Blade Air Mobility initiated with an Overweight at JPMorgan 07:23 BLDE JPMorgan analyst Bill Peterson initiated coverage of Blade Air Mobility with an Overweight rating and $16 price target. Blade is a "first mover" in urban air mobility and has "strong" growth momentum that should accelerate on rising brand awareness and with increased use of on-demand and scheduled flight services, Peterson tells investors in a research note. As an agnostic user of aircraft, Blade's model does not depend on the success of any one or a handful of electric vertical aircraft companies, says the analyst. H believes Blade may emerge as the leader of what can be considered "ride-sharing in the skies."
Regeneron initiated with a Buy at UBS & GBA 07:24 REGN
Not Another " UP " stock.
I have UPLAND and the one that is really good is UPSTART & Now we have..... UPWORK-!
Needham starts Upwork at Buy as it 'just scratches surface' of $1.3T TAM 07:33 UPWK
Biohaven Pharmaceutical to present recent data on Nurtec ODT 07:37 BHVN
My Son loves this character)
Not Another " UP " stock.
I have UPLAND and the one that is really good is UPSTART & Now we have..... UPWORK-!
Needham starts Upwork at Buy as it 'just scratches surface' of $1.3T TAM 07:33 UPWK
Biohaven Pharmaceutical to present recent data on Nurtec ODT 07:37 BHVN
My Son loves this character)
- Biohaven presenting 17 abstracts, including three late-breaking abstracts and four oral presentations, highlighting the efficacy and safety of Nurtec ODT as both an acute and preventive treatment of migraine
- Preventive effects of rimegepant evident as early as the first week of treatment and sustained after 12 weeks to be presented from Biohaven's Phase 2/3 Study
- A patient preference study demonstrated that those who used rimegepant for one year, four in five preferred it to their previous migraine medications, seven in 10 were satisfied, and nine in 10 experienced clinical improvement relative to baseline
I don't really see the importance of this reveal-- The feedback has been very good we all know that. The stk has held up great.
- Preventive effects of rimegepant evident as early as the first week of treatment and sustained after 12 weeks to be presented from Biohaven's Phase 2/3 Study
- A patient preference study demonstrated that those who used rimegepant for one year, four in five preferred it to their previous migraine medications, seven in 10 were satisfied, and nine in 10 experienced clinical improvement relative to baseline
I don't really see the importance of this reveal-- The feedback has been very good we all know that. The stk has held up great.